Lenetix launches screening study of diagnostic test to detect Down syndrome

The Lenetix PloidYX maternal blood test is claimed to be the most accurate and comprehensive test developed for the detection of fetal aneuploidies, the presence of extra chromosomes, which cause Down syndrome (T-21) and other chromosomal abnormalities.

Leonard Kellner, president and CEO of Lenetix, said: “We take deep pride in the technology we have developed because it has the potential to impact the lives of millions of women and their unborn children. Patients and doctors are constantly required to weigh the importance of an invasive and possibly unneeded procedure against the possible harm it could cause, and we are confident that this current institutional review board-approved assessment is the next step towards making that difficult decision unnecessary.”